Search

Your search keyword '"Ballanti S."' showing total 138 results
Start Over Author "Ballanti S."
138 results on '"Ballanti S."'

1. Bloodstream infections due to Gram-negative bacteria in patients with hematologic malignancies: updated epidemiology and risk factors for multidrug-resistant strains in an Italian perspective survey

Author

Trecarichi, Enrico Maria, Giuliano, G., Cattaneo, C., Ballanti, S., Criscuolo, Marianna, Candoni, A., Marchesi, F., Laurino, M., Dargenio, M., Fanci, R., Cefalo, M., Delia, M., Spolzino, A., Maracci, L., Bonuomo, V., Busca, A., Principe, M. I. D., Daffini, R., Simonetti, E., Dragonetti, Giulia, Zannier, M. E., Pagano, Livio, Tumbarello, Mario, Trecarichi E. M., Criscuolo M., Dragonetti G., Pagano L. (ORCID:0000-0001-8287-928X), Tumbarello M. (ORCID:0000-0002-9519-8552), Trecarichi, Enrico Maria, Giuliano, G., Cattaneo, C., Ballanti, S., Criscuolo, Marianna, Candoni, A., Marchesi, F., Laurino, M., Dargenio, M., Fanci, R., Cefalo, M., Delia, M., Spolzino, A., Maracci, L., Bonuomo, V., Busca, A., Principe, M. I. D., Daffini, R., Simonetti, E., Dragonetti, Giulia, Zannier, M. E., Pagano, Livio, Tumbarello, Mario, Trecarichi E. M., Criscuolo M., Dragonetti G., Pagano L. (ORCID:0000-0001-8287-928X), and Tumbarello M. (ORCID:0000-0002-9519-8552)

Abstract

Bloodstream infections (BSI) caused by Gram-negative bacteria (GNB) in patients with hematological malignancies (HM) have been associated with high mortality rates, particularly with infections caused by antibiotic-resistant strains. A multicenter cohort study including all consecutive episodes of GNB BSI in HM patients was conducted to update the epidemiology and antibiotic resistance patterns (compared to our previous survey conducted between 2009 and 2012) and investigate risk factors for GNB BSI due to multidrug-resistant (MDR) isolates. A total of 834 GNB were recovered in 811 BSI episodes from January 2016 to December 2018. Compared to the previous survey, there was a significant reduction in use of fluoroquinolone prophylaxis and a significant recovery in susceptibility rates to ciprofloxacin among Pseudomonas aeruginosa, Escherichia coli and Enterobacter cloacae isolates. In addition, there was a shift to a significantly increased susceptibility of P. aeruginosa isolates to ceftazidime, meropenem, and gentamicin. A total of 256/834 (30.7%) isolates were MDR. In multivariable analysis, MDR bacteria culture-positive surveillance rectal swabs, previous therapy with aminoglycosides and carbapenems, fluoroquinolone prophylaxis, and time at risk were independently associated with MDR GNB BSI. In conclusion, despite the persistence of a high prevalence of MDR GNB, there was a shift to a reduced use of fluoroquinolone prophylaxis and increased rates of susceptibility to fluoroquinolones in almost all isolates and to almost all antibiotics tested among P. aeruginosa isolates, compared to our previous survey. Fluoroquinolone prophylaxis and previous rectal colonization by MDR bacteria were independent risk factors for MDR GNB BSI in the present study.

Published
2023

2. P932: ON-DEMAND PLERIXAFOR WITH CYCLOPHOSPHAMIDE AND G-CSF FOR HEMATOPOIETIC STEM-CELL MOBILIZATION IN MULTIPLE MYELOMA PATIENTS: FINAL RESULTS OF THE MOZOBL06877 STUDY

Author

Mina, R., primary, Bonello, F., additional, Fazio, F., additional, Saccardi, R., additional, Bongarzoni, V., additional, Marchesi, F., additional, Bertuglia, G., additional, Curci, P., additional, Lemoli, R. M., additional, Ballanti, S., additional, Dentamaro, T., additional, Benevolo, G., additional, Capra, A., additional, Floris, R., additional, Tosi, P., additional, Olivieri, A., additional, Rota-Scalabrini, D., additional, Cangialosi, C., additional, Cavo, M., additional, Corradini, P., additional, Milone, G., additional, Boccadoro, M., additional, and Larocca, A., additional

Published
2022
Full Text
View/download PDF

3. PB1984: ELOTUZUMAB PLUS LENALIDOMIDE AND DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA: EXTENDED 3-YEAR FOLLOW-UP OF AN ITALIAN, MULTICENTER, EXPERIENCE OUTSIDE OF CONTROLLED CLINICAL TRIALS

Author

Bruzzese, A., primary, Derudas, D., additional, Galli, M., additional, Martino, E. A., additional, Rocco, S., additional, Conticello, C., additional, Califano, C., additional, Giuliani, N., additional, Mangicavalli, S., additional, Farina, G., additional, Lombardo, A., additional, Brunori, M., additional, Rossi, E., additional, Antonioli, E., additional, Ria, R., additional, Zambello, R., additional, Di Renzo, N., additional, Mele, G., additional, Marcacci, G., additional, Pietrantuono, G., additional, Palumbo, G., additional, Cascavilla, N., additional, Cerchione, C., additional, Belotti, A., additional, Criscuolo, C., additional, Uccello, G., additional, Curci, P., additional, Vigna, E., additional, Mendicino, F., additional, Iaccino, E., additional, Mimmi, S., additional, Botta, C., additional, Vincelli, D., additional, Sgherza, N., additional, Bonalumi, A., additional, Cupelli, L., additional, Stocchi, R., additional, Martino, M., additional, Ballanti, S., additional, Gangemi, D., additional, Gagliardi, A., additional, Gamberi, B., additional, Pompa, A., additional, Tripepi, G., additional, Frigeri, F., additional, Consoli, U., additional, Bringhen, S., additional, Zamagni, E., additional, Patriarca, F., additional, De Stefano, V., additional, Di Raimondo, F., additional, Palmieri, S., additional, Petrucci, M. T., additional, Offidani, M., additional, Musto, P., additional, Boccadoro, M., additional, Cavo, M., additional, Neri, A., additional, Morabito, F., additional, and Gentile, M., additional

Published
2022
Full Text
View/download PDF

4. Invasive aspergillosis in relapsed/refractory acute myeloid leukaemia patients: Results from SEIFEM 2016-B survey

Author

Del Principe, M. I., Dragonetti, Giulia, Conti, A., Verga, L., Ballanti, S., Fanci, R., Candoni, A., Marchesi, F., Cattaneo, C., Lessi, F., Fracchiolla, N., Spolzino, A., Prezioso, L., Delia, M., Potenza, L., Decembrino, N., Castagnola, C., Nadali, G., Picardi, M., Zama, D., Orciulo, E., Veggia, B., Garzia, M., Dargenio, M., Melillo, L., Manetta, S., Russo, D., Mancini, V., Piedimonte, M., Tisi, M. C., Toschi, N., Busca, A., Pagano, Livio, Dragonetti G., Pagano L. (ORCID:0000-0001-8287-928X), Del Principe, M. I., Dragonetti, Giulia, Conti, A., Verga, L., Ballanti, S., Fanci, R., Candoni, A., Marchesi, F., Cattaneo, C., Lessi, F., Fracchiolla, N., Spolzino, A., Prezioso, L., Delia, M., Potenza, L., Decembrino, N., Castagnola, C., Nadali, G., Picardi, M., Zama, D., Orciulo, E., Veggia, B., Garzia, M., Dargenio, M., Melillo, L., Manetta, S., Russo, D., Mancini, V., Piedimonte, M., Tisi, M. C., Toschi, N., Busca, A., Pagano, Livio, Dragonetti G., and Pagano L. (ORCID:0000-0001-8287-928X)

Abstract

Background: In patients with relapsed/refractory acute myeloid leukaemia (R/R AML) who received salvage chemotherapy, limited and not updated studies explored the incidence of invasive aspergillosis (IA) and the role of antifungal prophylaxis (AP). The aims of this multicentre retrospective ‘SEIFEM 2016-B’ study were as follows: (1) to evaluate the current rate and the outcome of proven/probable IA and (2) to assess the efficacy of AP, in a large ‘real life’ series of patient with R/R AML submitted to salvage chemotherapy. Results: Of 2250 R/R AML patients, a total of 74 cases of IA (5.1%) were recorded as follows: 10 (0.7%) proven and 64 (4.3%) probable. Information about AP were available in 73/74 (99%) patients. Fifty-eight (79%) breakthrough infections occurred, mainly during AP with posaconazole [25 (43%)]. The patients who received AP during salvage chemotherapy showed a benefit from antifungal therapy (AT) than patients who did not received AP [43 (86%) vs 7 (14%); p <.033]. In a multivariate analysis, AP and absence of severe mucositis had a significant favourable effect on overall response rate. Conclusion: Our data demonstrated that the incidence of IA during the salvage chemotherapy is similar to the past. Nevertheless, the attributable mortality rate (AMR) appears to be lower than that previously reported in R/R AML. Further prospective studies should be performed to confirm our preliminary observation and understand and the why a decreased AMR is reported in this setting of high-risk patients.

Published
2022

5. Superiority of VTD over TD Incorporated Into ASCT for Newly Diagnosed MM: A451

Author

Cavo, M, Zambello, R, Nozzoli, C, Gugliotta, L, Pantani, L, Patriarca, F, Petrucci, M T, Tacchetti, P, Galli, M, Ceccolini, M, Di Raimondo, F, Rossi, G, Zamagni, E, Bringhen, S, Narni, F, Tosi, P, Montefusco, V, Offidani, M, Brioli, A, Pallotti, M C, Spadano, T, Pescosta, N, Goldaniga, M, Ledda, A, Perrone, G, Petrucci, A, Caravita, T, Cascavilla, N, Gherlinzoni, F, De Stefano, V, Angelucci, E, Petti, M C, Ballanti, S, Callea, V, and Baccarani, M

Published
2009

6. Autologous haematopoietic stem-cell transplantation versus bortezomib–melphalan–prednisone, with or without bortezomib–lenalidomide–dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study

Author

Cavo, M. Gay, F. Beksac, M. Pantani, L. Petrucci, M.T. Dimopoulos, M.A. Dozza, L. van der Holt, B. Zweegman, S. Oliva, S. van der Velden, V.H.J. Zamagni, E. Palumbo, G.A. Patriarca, F. Montefusco, V. Galli, M. Maisnar, V. Gamberi, B. Hansson, M. Belotti, A. Pour, L. Ypma, P. Grasso, M. Croockewit, A. Ballanti, S. Offidani, M. Vincelli, I.D. Zambello, R. Liberati, A.M. Andersen, N.F. Broijl, A. Troia, R. Pascarella, A. Benevolo, G. Levin, M.-D. Bos, G. Ludwig, H. Aquino, S. Morelli, A.M. Wu, K.L. Boersma, R. Hajek, R. Durian, M. von dem Borne, P.A. Caravita di Toritto, T. Zander, T. Specchia, G. Waage, A. Gimsing, P. Mellqvist, U.-H. van Marwijk Kooy, M. Minnema, M. Mandigers, C. Cafro, A.M. Palmas, A. Carvalho, S. Spencer, A. Boccadoro, M. Sonneveld, P.

Abstract

Background: The emergence of highly active novel agents has led some to question the role of autologous haematopoietic stem-cell transplantation (HSCT) and subsequent consolidation therapy in newly diagnosed multiple myeloma. We therefore compared autologous HSCT with bortezomib–melphalan–prednisone (VMP) as intensification therapy, and bortezomib–lenalidomide–dexamethasone (VRD) consolidation therapy with no consolidation. Methods: In this randomised, open-label, phase 3 study we recruited previously untreated patients with multiple myeloma at 172 academic and community practice centres of the European Myeloma Network. Eligible patients were aged 18–65 years, had symptomatic multiple myeloma stage 1–3 according to the International Staging System (ISS), measurable disease (serum M protein >10 g/L or urine M protein >200 mg in 24 h or abnormal free light chain [FLC] ratio with involved FLC >100 mg/L, or proven plasmacytoma by biopsy), and WHO performance status grade 0–2 (grade 3 was allowed if secondary to myeloma). Patients were first randomly assigned (1:1) to receive either four 42-day cycles of bortezomib (1·3 mg/m2 administered intravenously or subcutaneously on days 1, 4, 8, 11, 22, 25, 29, and 32) combined with melphalan (9 mg/m2 administered orally on days 1–4) and prednisone (60 mg/m2 administered orally on days 1–4) or autologous HSCT after high-dose melphalan (200 mg/m2), stratified by site and ISS disease stage. In centres with a double HSCT policy, the first randomisation (1:1:1) was to VMP or single or double HSCT. Afterwards, a second randomisation assigned patients to receive two 28-day cycles of consolidation therapy with bortezomib (1·3 mg/m2 either intravenously or subcutaneously on days 1, 4, 8, and 11), lenalidomide (25 mg orally on days 1–21), and dexamethasone (20 mg orally on days 1, 2, 4, 5, 8, 9, 11, and 12) or no consolidation; both groups received lenalidomide maintenance therapy (10 mg orally on days 1–21 of a 28-day cycle). The primary outcomes were progression-free survival from the first and second randomisations, analysed in the intention-to-treat population, which included all patients who underwent each randomisation. All patients who received at least one dose of study drugs were included in the safety analyses. This study is registered with the EU Clinical Trials Register (EudraCT 2009-017903-28) and ClinicalTrials.gov (NCT01208766), and has completed recruitment. Findings: Between Feb 25, 2011, and April 3, 2014, 1503 patients were enrolled. 1197 patients were eligible for the first randomisation, of whom 702 were assigned to autologous HSCT and 495 to VMP; 877 patients who were eligible for the first randomisation underwent the second randomisation to VRD consolidation (n=449) or no consolidation (n=428). The data cutoff date for the current analysis was Nov 26, 2018. At a median follow-up of 60·3 months (IQR 52·2–67·6), median progression-free survival was significantly improved with autologous HSCT compared with VMP (56·7 months [95% CI 49·3–64·5] vs 41·9 months [37·5–46·9]; hazard ratio [HR] 0·73, 0·62–0·85; p=0·0001). For the second randomisation, the number of events of progression or death at data cutoff was lower than that preplanned for the final analysis; therefore, the results from the second protocol-specified interim analysis, when 66% of events were reached, are reported (data cutoff Jan 18, 2018). At a median follow-up of 42·1 months (IQR 32·3–49·2), consolidation therapy with VRD significantly improved median progression-free survival compared with no consolidation (58·9 months [54·0–not estimable] vs 45·5 months [39·5–58·4]; HR 0·77, 0·63–0·95; p=0·014). The most common grade ≥3 adverse events in the autologous HSCT group compared to the VMP group included neutropenia (513 [79%] of 652 patients vs 137 [29%] of 472 patients), thrombocytopenia (541 [83%] vs 74 [16%]), gastrointestinal disorders (80 [12%] vs 25 [5%]), and infections (192 [30%] vs 18 [4%]). 239 (34%) of 702 patients in the autologous HSCT group and 135 (27%) of 495 in the VMP group had at least one serious adverse event. Infection was the most common serious adverse event in each of the treatment groups (206 [56%] of 368 and 70 [37%] of 189). 38 (12%) of 311 deaths from first randomisation were likely to be treatment related: 26 (68%) in the autologous HSCT group and 12 (32%) in the VMP group, most frequently due to infections (eight [21%]), cardiac events (six [16%]), and second primary malignancies (20 [53%]). Interpretation: This study supports the use of autologous HSCT as intensification therapy and the use of consolidation therapy in patients with newly diagnosed multiple myeloma, even in the era of novel agents. The role of high-dose chemotherapy needs to be reassessed in future studies, in particular in patients with undetectable minimal residual disease after four-drug induction regimens including a monoclonal antiboby combined with an immunomodulatory agent and a proteasome inhibitor plus dexamethasone. Funding: Janssen and Celgene. © 2020 Elsevier Ltd

Published
2020

7. Bortezomib-dexamethasone as maintenance therapy or early retreatment at biochemical relapse versus observation in relapsed/refractory multiple myeloma patients: a randomized phase II study

Author

Mina, R. (Roberto), Belotti, A. (Angelo), Petrucci, M. (Maria), Zambello, R. (Renato), Capra, A. (Andrea), Di Lullo, G. (Giacomo), Ronconi, S. (Sonia), Pescosta, N. (Norbert), Grasso, M. (Mariella), Monaco, F. (Federico), Cellini, C. (Claudia), Gobbi, M. (Marco), Ballanti, S. (Stelvio), de Fabritiis, P. (Paolo), Mosca-Siez, M.L. (Maria Letizia), Marchetti, M. (Monia), Liberati, A.M., Offidani, M. (Massimo), Giuliani, N. (Nicola), Ria, R. (Roberto), Musto, P. (Pellegrino), Romano, A. (Alessandra), Sonneveld, P. (Pieter), Boccadoro, M. (Mario), Larocca, A. (Alessandra), Mina, R. (Roberto), Belotti, A. (Angelo), Petrucci, M. (Maria), Zambello, R. (Renato), Capra, A. (Andrea), Di Lullo, G. (Giacomo), Ronconi, S. (Sonia), Pescosta, N. (Norbert), Grasso, M. (Mariella), Monaco, F. (Federico), Cellini, C. (Claudia), Gobbi, M. (Marco), Ballanti, S. (Stelvio), de Fabritiis, P. (Paolo), Mosca-Siez, M.L. (Maria Letizia), Marchetti, M. (Monia), Liberati, A.M., Offidani, M. (Massimo), Giuliani, N. (Nicola), Ria, R. (Roberto), Musto, P. (Pellegrino), Romano, A. (Alessandra), Sonneveld, P. (Pieter), Boccadoro, M. (Mario), and Larocca, A. (Alessandra)

Published
2020
Full Text
View/download PDF

8. Bortezomib-dexamethasone as maintenance therapy or early retreatment at biochemical relapse versus observation in relapsed/refractory multiple myeloma patients: a randomized phase II study

Author

Mina, R, Belotti, A, Petrucci, MT, Zambello, R, Capra, A, Di Lullo, G, Ronconi, S, Pescosta, N, Grasso, M, Monaco, F, Cellini, C, Gobbi, M, Ballanti, S, de Fabritiis, P, Mosca-Siez, ML, Marchetti, M, Liberati, AM, Offidani, M, Giuliani, N, Ria, R, Musto, P, Romano, A, Sonneveld, Pieter, Boccadoro, M, Larocca, A, Mina, R, Belotti, A, Petrucci, MT, Zambello, R, Capra, A, Di Lullo, G, Ronconi, S, Pescosta, N, Grasso, M, Monaco, F, Cellini, C, Gobbi, M, Ballanti, S, de Fabritiis, P, Mosca-Siez, ML, Marchetti, M, Liberati, AM, Offidani, M, Giuliani, N, Ria, R, Musto, P, Romano, A, Sonneveld, Pieter, Boccadoro, M, and Larocca, A

Published
2020

9. Outcome of paraosseous extra-medullary disease in newly diagnosed multiple myeloma patients treated with new drugs

Author

Montefusco, V, Gay, F, Spada, S, De Paoli, L, Di Raimondo, F, Ribolla, R, Musolino, C, Patriarca, F, Musto, P, Galieni, P, Ballanti, S, Nozzoli, C, Cascavilla, N, Ben-Yehuda, D, Nagler, A, Hajek, R, Offidani, M, Liberati, AM, Sonneveld, Pieter, Cavo, M, Corradini, P, Boccadoro, M, Montefusco, V, Gay, F, Spada, S, De Paoli, L, Di Raimondo, F, Ribolla, R, Musolino, C, Patriarca, F, Musto, P, Galieni, P, Ballanti, S, Nozzoli, C, Cascavilla, N, Ben-Yehuda, D, Nagler, A, Hajek, R, Offidani, M, Liberati, AM, Sonneveld, Pieter, Cavo, M, Corradini, P, and Boccadoro, M

Published
2020

10. Candidaemia in haematological malignancy patients from a SEIFEM study: Epidemiological patterns according to antifungal prophylaxis

Author

Posteraro, Brunella, De Carolis, Elena, Criscuolo, Marianna, Ballanti, S., De Angelis, Giulia, Del Principe, M. I., Delia, M., Fracchiolla, N., Marchesi, F., Nadali, G., Picardi, Stefano Maria, Piccioni, A. L., Verga, L., Candoni, A., Busca, A., Sanguinetti, Maurizio, Pagano, Livio, Muggeo, P., Stanzani, M., Cattaneo, C., Russo, D., Vacca, A., Fanci, R., De Paolis, M. R., Mancini, V., Lessi, F., Rossetti, E., Decembrino, N., Facchini, L., Dragonetti, Giulia, Ferrari, A., Vallero, S., Posteraro B. (ORCID:0000-0002-1663-7546), De Carolis E. (ORCID:0000-0003-4757-7256), Criscuolo M., De Angelis G. (ORCID:0000-0002-7087-7399), Picardi M., Sanguinetti M. (ORCID:0000-0002-9780-7059), Pagano L. (ORCID:0000-0001-8287-928X), Dragonetti G., Posteraro, Brunella, De Carolis, Elena, Criscuolo, Marianna, Ballanti, S., De Angelis, Giulia, Del Principe, M. I., Delia, M., Fracchiolla, N., Marchesi, F., Nadali, G., Picardi, Stefano Maria, Piccioni, A. L., Verga, L., Candoni, A., Busca, A., Sanguinetti, Maurizio, Pagano, Livio, Muggeo, P., Stanzani, M., Cattaneo, C., Russo, D., Vacca, A., Fanci, R., De Paolis, M. R., Mancini, V., Lessi, F., Rossetti, E., Decembrino, N., Facchini, L., Dragonetti, Giulia, Ferrari, A., Vallero, S., Posteraro B. (ORCID:0000-0002-1663-7546), De Carolis E. (ORCID:0000-0003-4757-7256), Criscuolo M., De Angelis G. (ORCID:0000-0002-7087-7399), Picardi M., Sanguinetti M. (ORCID:0000-0002-9780-7059), Pagano L. (ORCID:0000-0001-8287-928X), and Dragonetti G.

Abstract

Background: Candidaemia is an important infectious complication for haematological malignancy patients. Antifungal prophylaxis reduces the incidence of candidaemia but may be associated with breakthrough candidaemia. Objective: To analyse the Candida species’ distribution and relative antifungal susceptibility profiles of candidaemia episodes in relation to the use of antifungal prophylaxis among Italian SEIFEM haematology centres. Methodology: This multicentre retrospective observational SEIFEM study included 133 single-species candidaemia episodes of haematological malignancy patients for whom antifungal susceptibility testing results of blood Candida isolates were available between 2011 and 2015. Each participating centre provided both clinical and microbiological data. Results: Non-Candida albicans Candida (NCAC) species were the mostly isolated species (89, 66.9%), which accounted for C parapsilosis (35, 26.3%), C glabrata (16, 12.0%), C krusei (14, 10.5%), C tropicalis (13, 9.8%) and uncommon species (11, 8.3%). C albicans caused the remaining 44 (33.1%) episodes. Excluding 2 C albicans isolates, 23 of 25 fluconazole-resistant isolates were NCAC species (14 C krusei, 6 C glabrata, 2 C parapsilosis and 1 C tropicalis). Fifty-six (42.1%) of 133 patients developed breakthrough candidaemia. Systemic antifungal prophylaxis consisted of azoles, especially fluconazole and posaconazole, in 50 (89.3%) of 56 patients in whom a breakthrough candidaemia occurred. Interestingly, all these patients tended to develop a C krusei infection (10/56, P =.02) or a fluconazole-resistant isolate’s infection (14/50, P =.04) compared to patients (4/77 and 10/77, respectively) who did not have a breakthrough candidaemia. Conclusions: Optimisation of prophylactic strategies is necessary to limit the occurrence of breakthrough candidaemia and, importantly, the emergence of fluconazole-resistant NCAC isolates’ infections in

Published
2020

12. 'Real-life' analysis of the role of antifungal prophylaxis in preventing invasive aspergillosis in AML patients undergoing consolidation therapy: Sorveglianza Epidemiologica Infezioni nelle Emopatie (SEIFEM) 2016 study

Author

Del Principe MI, Dragonetti, G, Verga, L, Candoni, A, Marchesi, F, Cattaneo, C, Delia, M, Potenza, L, Farina, F, Ballanti, S, Decembrino, N, Castagnola, C, Nadali, G, Fanci, R, Orciulo, E, Veggia, B, Offidani, M, Melillo, L, Manetta, S, Tumbarello, M, Venditti, A, Busca, A, Aversa, F, and Pagano, L

Subjects
antifungal prophylaxis , consolidation therapy. AML
Published
2019

13. PF602 OUTCOME OF EXTRA-MEDULLARY DISEASE IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS TREATED WITH NEW DRUGS

Author

Montefusco, V., primary, Gay, F., additional, Spada, S., additional, De Paoli, L., additional, Raimondo, F. Di, additional, Ribolla, R., additional, Musolino, C., additional, Patriarca, F., additional, Musto, P., additional, Galieni, P., additional, Ballanti, S., additional, Nozzoli, C., additional, Cascavilla, N., additional, Ben-Yehuda, D., additional, Nagler, A., additional, Hajek, R., additional, Offidani, M., additional, Liberati, A.M., additional, Sonneveld, P., additional, Cavo, M., additional, Corradini, P., additional, and Boccadoro, M., additional

Published
2019
Full Text
View/download PDF

14. PS1267 ISAVUCONAZOLE IN HEMATOLOGICAL PATIENTS: FINAL RESULTS OF A REAL-LIFE MULTICENTER SEIFEM (SORVEGLIANZA EPIDEMIOLOGICA DELLE INFEZIONI NELLE EMOPATIE) STUDY

Author

Cattaneo, C., primary, Gramegna, D., additional, Busca, A., additional, Farina, F., additional, Candoni, A., additional, Piedimonte, M., additional, Fracchiolla, N.S., additional, Pagani, C., additional, Principe, M.I. Del, additional, Tisi, M.C., additional, Maracci, L., additional, Fanci, R., additional, Ballanti, S., additional, Spolzino, A., additional, Criscuolo, M., additional, Marchesi, F., additional, Nadali, G., additional, Delia, M., additional, Picardi, M., additional, Sciumé, M., additional, Tumbarello, M., additional, Rossi, G., additional, and Pagano, L., additional

Published
2019
Full Text
View/download PDF

15. Lenalidomide Maintenance with or without Prednisone in Newly Diagnosed Myeloma Patients: A Pooled Analysis

Author

Bonello, F., Pulini, S., Ballanti, S., Gentile, M. (Massimo), Spada, S, Annibali, O., Omedé, P. (Paola), Ronconi, S., Cangialosi, C., Podda, L., Palmas, A., Malfitano, A., Rivoli, G., Belotti, A., Ciambelli, F., Vincelli, ID, Cafro, A.M., Innao, V., Palumbo, A., Sonneveld, P. (Pieter), Spencer, A. (Andrew), Hàjek, R. (Roman), Boccadoro, M. (Mario), Gay, F. (Francesca), Bonello, F., Pulini, S., Ballanti, S., Gentile, M. (Massimo), Spada, S, Annibali, O., Omedé, P. (Paola), Ronconi, S., Cangialosi, C., Podda, L., Palmas, A., Malfitano, A., Rivoli, G., Belotti, A., Ciambelli, F., Vincelli, ID, Cafro, A.M., Innao, V., Palumbo, A., Sonneveld, P. (Pieter), Spencer, A. (Andrew), Hàjek, R. (Roman), Boccadoro, M. (Mario), and Gay, F. (Francesca)

Abstract

We conducted a pooled analysis of two phase III trials, RV-MM-EMN-441 and EMN01, to compare maintenance with lenalidomide-prednisone vs. lenalidomide in newly diagnosed transplant-eligible and -ineligible myeloma patients. Primary endpoints were progression-free survival, progression-free survival 2 and overall survival with both regimens. A secondary aim was to evaluate the impact of duration of maintenance on overall survival and on outcome after relapse. A total of 625 patients (lenalidomide-prednisone arm, n = 315; lenalidomide arm, n = 310) were analyzed. The median follow-up was 58 months. Median progression-free survival (25 vs. 19 months; p = 0.08), progression-free survival 2 (56 vs. 49 months; p = 0.9) and overall survival (73 months vs. NR; p = 0.08) were not significantly different between the two arms. Toxicity profiles of lenalidomide-prednisone and lenalidomide were similar, with the exception of neutropenia that was higher in the lenalidomide arm (grade ≥ 3: 9% vs. 19%, p < 0.001), without an increase in the rate of infections. Overall survival (median NR vs. 49 months, p < 0.001), progression-free survival from relapse (median 35 vs. 24 months, p = 0.004) and overall survival from relapse (median not reached vs. 41 months, p = 0.002) were significantly longer in patients continuing maintenance for ≥2 years. We showed that the addition of prednisone at 25 or 50 mg every other day (eod) to lenalidomide maintenance did not induce any significant advantage.

Published
2019
Full Text
View/download PDF

16. Lenalidomide Maintenance with or without Prednisone in Newly Diagnosed Myeloma Patients: A Pooled Analysis

Author

Bonello, F, Pulini, S, Ballanti, S, Gentile, M, Spada, S, Annibali, O, Omede, P, Ronconi, S, Cangialosi, C, Podda, L, Palmas, A, Malfitano, A, Rivoli, G, Belotti, A, Ciambelli, F, Vincelli, ID, Cafro, AM, Innao, V, Palumbo, A, Sonneveld, Pieter, Spencer, A, Hajek, R, Boccadoro, M, Gay, F, Bonello, F, Pulini, S, Ballanti, S, Gentile, M, Spada, S, Annibali, O, Omede, P, Ronconi, S, Cangialosi, C, Podda, L, Palmas, A, Malfitano, A, Rivoli, G, Belotti, A, Ciambelli, F, Vincelli, ID, Cafro, AM, Innao, V, Palumbo, A, Sonneveld, Pieter, Spencer, A, Hajek, R, Boccadoro, M, and Gay, F

Published
2019

17. Bloodstream infections caused by Escherichia coli in onco-haematological patients: Risk factors and mortality in an Italian prospective survey

Author

Trecarichi, Enrico Maria, Giuliano, Gabriele, Cattaneo, C., Ballanti, S., Criscuolo, Marianna, Candoni, A., Marchesi, F., Laurino, M., Dargenio, M., Fanci, R., Cefalo, M., Delia, M., Spolzino, A., Maracci, L., Nadali, G., Busca, A., Del Principe, M. I., Daffini, R., Simonetti, E., Dragonetti, G., Zannier, M. E., Pagano, Livio, Tumbarello, Mario, Trecarichi E. M., Criscuolo M., Pagano L. (ORCID:0000-0001-8287-928X), Tumbarello M. (ORCID:0000-0002-9519-8552), Trecarichi, Enrico Maria, Giuliano, Gabriele, Cattaneo, C., Ballanti, S., Criscuolo, Marianna, Candoni, A., Marchesi, F., Laurino, M., Dargenio, M., Fanci, R., Cefalo, M., Delia, M., Spolzino, A., Maracci, L., Nadali, G., Busca, A., Del Principe, M. I., Daffini, R., Simonetti, E., Dragonetti, G., Zannier, M. E., Pagano, Livio, Tumbarello, Mario, Trecarichi E. M., Criscuolo M., Pagano L. (ORCID:0000-0001-8287-928X), and Tumbarello M. (ORCID:0000-0002-9519-8552)

Abstract

Bloodstream infections (BSIs) remain life-threatening complications in the clinical course of patients with haematological malignancies (HM) and Escherichia coli represent one of the most frequent cause of such infections. In this study, we aimed to describe risk factors for resistance to third generation cephalosporins and prognostic factors, including the impact of third generation cephalosporins resistance, in patients with HM and BSIs caused by E. coli. Three hundred forty-two cases of E. coli BSIs were collected during the study period (from January 2016 to December 2017). The percentage of resistance to third generation cephalosporins was 25.7%. In multivariate analysis, the variables recent endoscopic procedures, culture-positive surveillance rectal swabs for multidrug-resistant bacteria, antibiotic prophylaxis with fluoroquinolones, and prolonged neutropenia were independently associated with bloodstream infections caused by a third generation cephalosporins resistant E. coli. The overall 30-day mortality rate was 7.1%. Cox regression revealed that significant predictors of mortality were acute hepatic failure, septic shock, male sex, refractory/relapsed HM, and third generation cephalosporins resistance by E. coli isolate. In conclusion, resistance to third generation cephalosporins adversely affected the outcomes of bloodstream infections caused by E. coli in our cohort of HM patients. We also found a significant correlation between prophylaxis with fluoroquinolones and resistance to third generation cephalosporins by E. coli isolates.

Published
2019

18. Fungaemia in haematological malignancies: SEIFEM-2015 survey

Author

Criscuolo, M., Marchesi, F., Candoni, A., Cattaneo, C., Nosari, A., Veggia, B., Verga, L., Fracchiolla, N., Vianelli, N., Del Principe, M. I., Picardi, M., Tumbarello, M., Aversa, F., Busca, A., Pagano, L., Dragonetti, G., Ballanti, S., Delia, M., Nadali, G., Sciume, M., Castagnola, C., Ferrari, A., Mancini, V., Decembrino, N., Spolzino, A., Iovino, L., Martino, B., Vacca, A., Calore, E., Fanci, R., Lessi, F., Vallero, S., Zama, D., Cesaro, S., De Paolis, M. R., Facchini, L., Muggeo, P., Offidani, M., Perruccio, K., Russo, D., Criscuolo M, Marchesi F, Candoni A, Cattaneo C, Nosari A, Veggia B, Verga L, Fracchiolla N, Vianelli N, Del Principe MI, Picardi M, Tumbarello M, Aversa F, Busca A, Pagano L, SEIFEM Group: Giulia Dragonetti, Stelvio Ballanti, Mario Delia, Gianpaolo Nadali, Sciumè M, Castagnola C, Ferrari A, Mancini V, Decembrino N, Spolzino A, Iovino L, Martino B, Vacca A, Calore E, Fanci R, Lessi F, Vallero S, Zama D, Cesaro S, De Paolis M, Facchini L, Muggeo P, Offidani M, Perruccio K, Russo D., Criscuolo, Marianna, Marchesi, Francesco, Candoni, Anna, Cattaneo, Chiara, Nosari, Annamaria, Veggia, Barbara, Verga, Luisa, Fracchiolla, Nicola, Vianelli, Nicola, Del Principe, Maria Ilaria, Picardi, Marco, Tumbarello, Mario, Aversa, Franco, Busca, Alessandro, and Pagano, Livio

Subjects
Adult, Male, medicine.medical_specialty, Adolescent, medicine.medical_treatment, Clinical Biochemistry, Prevalence, 030204 cardiovascular system & hematology, Biochemistry, Young Adult, 03 medical and health sciences, acute leukaemias, candidemia, fungaemia, 0302 clinical medicine, Risk Factors, Yeasts, Internal medicine, acute leukemias, Epidemiology, Fungemia, Hematological malignancies, medicine, Aged, Candidemia, Child, Female, Fungemia, Hematologic Neoplasms, Humans, Italy, Middle Aged, Prognosis, Retrospective Studies, acute leukemia, 030212 general & internal medicine, Cause of death, Hematology, business.industry, Septic shock, Mortality rate, General Medicine, bacterial infections and mycoses, medicine.disease, Settore MED/15 - MALATTIE DEL SANGUE, fungemia, business, Central venous catheter
Abstract

BACKGROUND: Fungal infections are still a relevant challenge for clinicians involved in the cure of patients with cancer. We retrospectively reviewed charts of hospitalized patients with hematological malignancies (HMs), in which a documented fungemia was diagnosed between January 2011 and December 2015 at 28 adult and 6 pediatric Italian Hematology Departments. METHODS: During the study period we recorded 215 fungal blood stream infections (BSI). Microbiological analyses documented that BSI was due to molds in 17 patients (8%) and yeasts in 198 patients (92%), being Candida spp identified in 174 patients (81%). RESULTS: Mortality rates were 70% and 39% for mold and yeast infections, respectively. Infection was the main cause of death in 53% of the mold and 18% of the yeast groups. At the multivariate analysis, ECOG ≥2 and septic shock were significantly associated with increased mortality, and removal of CVC survival was found to be protective. When considering patients with candidemia only, ECOG >2 and removal of CVC were statistically associated with overall mortality. CONCLUSIONS: Although candidemia represents a group of BSI with a good prognosis, its risk factors largely overlap with those identified for all fungemias, even though the candidemia-related mortality is lower when compared to other fungal BSI. Management of fungal BSI is still a complex issue, in which both patients and disease characteristics should be focused to address a personalized approach. This article is protected by copyright. All rights reserved.

Published
2019
Full Text
View/download PDF

19. Phase 1/2 study of weekly carfilzomib, cyclophosphamide, dexamethasone in newly diagnosed transplant-ineligible myeloma

Author

Bringhen, S. (Sara), D'Agostino, M. (M.), De Paoli, L. (L.), Montefusco, V. (Vittorio), Liberati, A.M., Galieni, P. (P.), Grammatico, S. (S.), Muccio, V.E. (V. E.), Esma, F. (F.), De Angelis, C. (C.), Musto, P. (Pellegrino), Ballanti, S. (S.), Offidani, M. (Massimo), Petrucci, M. (Maria), Gaidano, G. (G.), Corradini, P. (P.), Palumbo, A. (Antonio), Sonneveld, P. (Pieter), Boccadoro, M. (Mario), Bringhen, S. (Sara), D'Agostino, M. (M.), De Paoli, L. (L.), Montefusco, V. (Vittorio), Liberati, A.M., Galieni, P. (P.), Grammatico, S. (S.), Muccio, V.E. (V. E.), Esma, F. (F.), De Angelis, C. (C.), Musto, P. (Pellegrino), Ballanti, S. (S.), Offidani, M. (Massimo), Petrucci, M. (Maria), Gaidano, G. (G.), Corradini, P. (P.), Palumbo, A. (Antonio), Sonneveld, P. (Pieter), and Boccadoro, M. (Mario)

Abstract

This multicentre, open-label phase 1/2 trial determined safety and efficacy of weekly carfilzomib plus cyclophosphamide-dexamethasone (wKCyd) in newly diagnosed multiple myeloma (NDMM) patients aged ≥65 years or transplant ineligible. Patients received wKCyd for up to nine 28-day cycles, followed by maintenance with carfilzomib until progression/intolerance. The phase 1 portion used a 3+3 dose-escalation scheme to determine the maximum tolerated dose of weekly carfilzomib: 12 patients received wKCyd with carfilzomib doses of 45, 56 and 70 mg/m 2. The recommended phase 2 dose was established at 70 mg/m 2 and 54 patients (phase 1 and 2) received weekly carfilzomib 70 mg/m 2: 85% of them achieved ≥partial response (PR), 66% ≥very good PR, 30%≥near-complete response (CR) and 15% CR. Responses improved in 40 patients who started maintenance: 98% achieved ≥PR, including 29% CR and 10% stringent CR. After a median follow-up of 18 months, the 2-year progression-free survival and overall survival rates were 53.2% and 81%, respectively. The most frequent grade 3-5 toxicities were neutropenia (22%) and cardiopulmonary adverse events (9%). This is the first study of weekly carfilzomib plus an alkylating agent in elderly patients with NDMM. wKCyd was effective, with an acceptable risk/benefit ratio, and thus can be a valid option in this setting.

Published
2018
Full Text
View/download PDF

20. Phase 1/2 study of weekly carfilzomib, cyclophosphamide, dexamethasone in newly diagnosed transplant-ineligible myeloma

Author

Bringhen, S, D'Agostino, M, De Paoli, L, Montefusco, V, Liberati, AM, Galieni, P, Grammatico, S, Muccio, VE, Esma, F, De Angelis, C, Musto, P, Ballanti, S, Offidani, M, Petrucci, MT, Gaidano, G, Corradini, P, Palumbo, A, Sonneveld, Pieter, Boccadoro, M, Bringhen, S, D'Agostino, M, De Paoli, L, Montefusco, V, Liberati, AM, Galieni, P, Grammatico, S, Muccio, VE, Esma, F, De Angelis, C, Musto, P, Ballanti, S, Offidani, M, Petrucci, MT, Gaidano, G, Corradini, P, Palumbo, A, Sonneveld, Pieter, and Boccadoro, M

Published
2018

21. Bloodstream infections in haematological cancer patients colonized by multidrug-resistant bacteria

Author

Cattaneo, C., Di Blasi, R., Skert, C., Candoni, A., Martino, B., Di Renzo, N., Delia, M., Ballanti, S., Marchesi, F., Mancini, V., Orciuolo, E., Cesaro, S., Prezioso, L., Fanci, R., Nadali, G., Chierichini, A., Facchini, L., Picardi, M., Malagola, M., Orlando, V., Trecarichi, E. M., Tumbarello, M., Aversa, F., Rossi, G., Pagano, L., Passi, Angela, Gramegna, Doriana, Russo, Domenico, Lazzarotto, Davide, Rotilio, Domenico, De Paolis, Maria Rosaria, Simonetti, Edoardo, Innocente, Maria Alessandra, Spadea, Antonio, Mazziotta, Francesco, Pegoraro, Anna, Spolzino, Angelica, Turri, Gloria, Veggia, Barbara, Tumbarello, M. (ORCID:0000-0002-9519-8552), Pagano, L. (ORCID:0000-0001-8287-928X), Cattaneo, C., Di Blasi, R., Skert, C., Candoni, A., Martino, B., Di Renzo, N., Delia, M., Ballanti, S., Marchesi, F., Mancini, V., Orciuolo, E., Cesaro, S., Prezioso, L., Fanci, R., Nadali, G., Chierichini, A., Facchini, L., Picardi, M., Malagola, M., Orlando, V., Trecarichi, E. M., Tumbarello, M., Aversa, F., Rossi, G., Pagano, L., Passi, Angela, Gramegna, Doriana, Russo, Domenico, Lazzarotto, Davide, Rotilio, Domenico, De Paolis, Maria Rosaria, Simonetti, Edoardo, Innocente, Maria Alessandra, Spadea, Antonio, Mazziotta, Francesco, Pegoraro, Anna, Spolzino, Angelica, Turri, Gloria, Veggia, Barbara, Tumbarello, M. (ORCID:0000-0002-9519-8552), and Pagano, L. (ORCID:0000-0001-8287-928X)

Abstract

Infections by multidrug-resistant (MDR) bacteria are a worrisome phenomenon in hematological patients. Data on the incidence of MDR colonization and related bloodstream infections (BSIs) in haematological patients are scarce. A multicentric prospective observational study was planned in 18 haematological institutions during a 6-month period. All patients showing MDR rectal colonization as well as occurrence of BSI at admission were recorded. One-hundred forty-four patients with MDR colonization were observed (6.5% of 2226 admissions). Extended spectrum beta-lactamase (ESBL)-producing (ESBL-P) enterobacteria were observed in 64/144 patients, carbapenem-resistant (CR) Gram-negative bacteria in 85/144 and vancomycin-resistant enterococci (VREs) in 9/144. Overall, 37 MDR-colonized patients (25.7%) developed at least one BSI; 23 of them (62.2%, 16% of the whole series) developed BSI by the same pathogen (MDRrel BSI), with a rate of 15.6% (10/64) for ESBL-P enterobacteria, 14.1% (12/85) for CR Gram-negative bacteria and 11.1% (1/9) for VRE. In 20/23 cases, MDRrel BSI occurred during neutropenia. After a median follow-up of 80 days, 18 patients died (12.5%). The 3-month overall survival was significantly lower for patients colonized with CR Gram-negative bacteria (83.6%) and VRE (77.8%) in comparison with those colonized with ESBL-P enterobacteria (96.8%). CR-rel BSI and the presence of a urinary catheter were independent predictors of mortality. MDR rectal colonization occurs in 6.5% of haematological inpatients and predicts a 16% probability of MDRrel BSI, particularly during neutropenia, as well as a higher probability of unfavourable outcomes in CR-rel BSIs. Tailored empiric antibiotic treatment should be decided on the basis of colonization.

Published
2018

23. Phase 1/2 study of weekly carfilzomib, cyclophosphamide, dexamethasone in newly diagnosed transplant-ineligible myeloma

Author

Bringhen, S, primary, D'Agostino, M, additional, De Paoli, L, additional, Montefusco, V, additional, Liberati, A M, additional, Galieni, P, additional, Grammatico, S, additional, Muccio, V E, additional, Esma, F, additional, De Angelis, C, additional, Musto, P, additional, Ballanti, S, additional, Offidani, M, additional, Petrucci, M T, additional, Gaidano, G, additional, Corradini, P, additional, Palumbo, A, additional, Sonneveld, P, additional, and Boccadoro, M, additional

Published
2017
Full Text
View/download PDF

25. BENDAMUSTINE, BORTEZOMIB AND DEXAMETHASONE (BVD) EXERT A SUBSTANTIAL ACTIVITY WITH A MANAGEABLE TOXICITY IN PATIENTS WITH RELAPSED-REFRACTORY MULTIPLE MYELOMA

Author

Offidani, M., Corvatta, L., Maracci, L., Liberati, Am, Ballanti, S., Attoli co, I., Caraffa, P., Alesiani, F., Caravita di Toritto, T., Gentili, S., Tosi, P., Brunori, M., Derudas, D., Ledda, A., Gozzetti, A., Cellini, C., Malerba, L., Mele, A., Felici, S., Galimberti, Sara, Mondello, P., Pulini, S., Coppetelli, U., Fraticelli, P., and Leoni, P.

Published
2014

28. Early Mortality in Elderly Patients With Newly Diagnosed Multiple Myeloma Treated With Novel Agents

Author

Larocca, A., primary, Bringhen, S., additional, Petrucci, M.T., additional, Offidani, M., additional, Benevolo, G., additional, Galli, M., additional, Patriarca, F., additional, Ballanti, S., additional, Palladino, C., additional, Pescosta, N., additional, Grasso, M., additional, Evangelista, A., additional, Spada, S., additional, Pezzati, S., additional, Pulini, S., additional, Bernardini, A., additional, Rota-Scalabrini, D., additional, Morabito, F., additional, Tosi, P., additional, Oliva, S., additional, Baldini, M., additional, Marasca, R., additional, Finsinger, P., additional, Cellini, C., additional, Ria, R., additional, Aitoro, G., additional, Hajek, R., additional, Boccadoro, M., additional, and Palumbo, A., additional

Published
2015
Full Text
View/download PDF

30. IMPACT OF UPFRONT BORTEZOMIB-BASED REGIMENS ON CLINICAL OUTCOMES OF NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS ACCORDING TO CYTOGENETIC ABNORMALITIES BY FISH ANALYSIS

Author

Cavo, M., Palumbo, A., Bringhen, S., DI RAIMONDO, Francesco, Patriarca, F., Rossi, D., Levi, A., Offidani, M., Montefusco, V., Narni, F., Zambello, R., Benevolo, G., Grasso, M., Falcone, A., Musto, P., Guglielmelli, T., Gherlinzoni, F., Gottardi, D., Musolino, C., DI RENZO, N., Masini, L., Cangialosi, C., Dore, F., Ballanti, S., Storti, S., Angelucci, E., Vallone, R., Magarotto, V., Morabito, F., Tosi, P., and Boccadoro, M.

Published
2010

31. Superior complete response rate and progression-free survival after autologous stem-cell transplantation (ASCT) incorporating velcade-thalidomide-dexamethasone (VTD)compared to thalidomide-dexametha-sone (TD) in newly diagnosed multiple myelona

Author

Cavo, M, Pantani, L, Patriarca, F, Petrucci, M. T., Tacchetti, P, Galli, L, DI RAIMONDO, Francesco, Crippa, C, Bringhen, S, Montefusco, V, Narni, F, Offidani, M, Spadano, T, Olivero, B, Pescosta, N, Caravita, T, Cellini, C, Ledda, A, Falcone, A, Agostini, P, Cavraro, M, Masini, L, Nozzoli, C, Ballanti, S, Derudas, D, DE STEFANO, V, Pisani, F, Califano, C, Callea, V, Catania, G, Nozza, A, Palmieri, S, Peccatori, J, Baraldi, A, Fattori, Pp, Pasini, S, Musto, P, Grasso, M, Ballerini, F, Cangialosi, C, Catalano, L, Morandi, S, Ronconi, S, and Baccarani, M.

Published
2009

33. Systemic antifungal treatment after posaconazole prophylaxis: results from the SEIFEM 2010-C survey

Author

Pagano, Livio, Verga, L, Busca, A, Martino, B, Mitra, Me, Fanci, R, Ballanti, S, Picardi, M, Castagnola, C, Cattaneo, C., Nadali, G, Nosari, A, Candoni, A, Caira, Morena, Salutari, P, Lessi, F, D'Aversa, Franco, Tumbarello, Mario, Pagano, Livio (ORCID:0000-0001-8287-928X), Tumbarello, Mario (ORCID:0000-0002-9519-8552), Pagano, Livio, Verga, L, Busca, A, Martino, B, Mitra, Me, Fanci, R, Ballanti, S, Picardi, M, Castagnola, C, Cattaneo, C., Nadali, G, Nosari, A, Candoni, A, Caira, Morena, Salutari, P, Lessi, F, D'Aversa, Franco, Tumbarello, Mario, Pagano, Livio (ORCID:0000-0001-8287-928X), and Tumbarello, Mario (ORCID:0000-0002-9519-8552)

Abstract

To investigate the incidence, treatment and outcome of breakthrough invasive fungal infections (IFIs) in adult acute myeloid leukaemia (AML) patients after posaconazole prophylaxis.

Published
2014

34. Systemic antifungal treatment after posaconazole prophylaxis: results from the SEIFEM 2010-C survey

Author

Pagano, L., primary, Verga, L., additional, Busca, A., additional, Martino, B., additional, Mitra, M. E., additional, Fanci, R., additional, Ballanti, S., additional, Picardi, M., additional, Castagnola, C., additional, Cattaneo, C., additional, Nadali, G., additional, Nosari, A., additional, Candoni, A., additional, Caira, M., additional, Salutari, P., additional, Lessi, F., additional, Aversa, F., additional, and Tumbarello, M., additional

Published
2014
Full Text
View/download PDF

35. Decreased bone mineral density after autologous stem cell transplantation

Author

Ria, R., Scarponi, A., Falzetti, F., Ballanti, S., Di Ianni, M., Cimminiello, M., Gasbarrino, C., Pallone, B., Russo, F., Cirulli, T., Vacca, A., Dammanco, F., Mannarino, Elmo, Martelli, Massimo Fabrizio, and Tabilio, Antonio

Subjects
cellule staminali, trapianto autologo, minerale osseo
Published
2003

38. Full-haplotype mismatched HSCT for high risk acute myeloid leukemia (AML)

Author

Aversa, Franco, Terenzi, A., Ballanti, S., Felicini, R., Carotti, A., Falcinelli, F., Tabilio, Antonio, Falzetti, Franca, Velardi, Andrea, Capponi, M., Santucci, A., and Martelli, Massimo Fabrizio

Subjects
trapianto incompatibile, celluel staminali ematopoieticheleucemia mieloide acuta
Published
2002

41. Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma

Author

Cavo, M, Pantani, L, Petrucci, M, Patriarca, F, Zamagni, E, Donnarumma, D, Crippa, C, Boccadoro, M, Perrone, G, Falcone, A, Nozzoli, C, Zambello, R, Masini, L, Furlan, A, Brioli, A, Derudas, D, Ballanti, S, Dessanti, M, De Stefano, V, Carella, A, Marcatti, M, Nozza, A, Ferrara, F, Callea, V, Califano, C, Pezzi, A, Baraldi, A, Grasso, M, Musto, P, Palumbo, A, Tosi, P, Motta, M, Rizzi, S, Fanin, R, Buttignol, S, Foà, R, Levi, A, Calabrese, E, Rambaldi, A, Galli, M, Rossi, G, Ferrari, S, Bringhen, S, Leoni, P, Offidani, M, Polloni, C, Corradini, P, Montefusco, V, Torelli, G, Narni, F, Fioritoni, G, Spadano, A, Cortelazzo, S, Pescosta, N, Billio, A, Lambertenghi Deliliers, G, Baldini, L, Onida, F, Annaloro, C, La Nasa, G, Ledda, A, Zaccaria, A, Cellini, C, De Fabritiis, P, Caravita, T, Siniscalchi, A, Cascavilla, N, Bosi, A, Semenzato, G, Gugliotta, L, Merli, F, Gherlinzoni, F, Angelucci, E, Martelli, M, Petti, M, Pisani, F, Leone, G, Rossi, E, Za, T, Fianchi, L, Catania, G, Spriano, M, Ciceri, F, Peccatori, J, Girlanda, S, Santoro, A, Castagna, L, Palmieri, S, Nobile, F, D'Arco, A, Levis, A, Primon, V, Tamiazzo, S, Guardigni, L, Pasini, S, Gallamini, A, Pietrantuono, G, Martorelli, M, Fattori, P, Pasquini, E, Galieni, P, Ruggieri, M, Morandi, S, Tajana, M, Amadori, D, Ronconi, S, Cangini, D, Ceccolini, M, Gobbi, M, Ballerini, F, Pane, F, Catalano, L, Cangialosi, C, Vallisa, D, Lazzaro, A, Paladini, G, De Sabbata, G, Mozzana, R, Ciambelli, F, Pinotti, G, Rodeghiero, F, Elice, F, Cantore, N, Volpe, S, Pavone, V, Mele, A, Pogliani, E, Rossini, F, Liberati, A, Majolino, I, De Rosa, L, Amadori, S, Rizzo, M, Lauria, F, Gozzetti, A, Aglietta, M, Capaldi, A, Quarta, G, Mele, G, Storti, S, Fraticelli, V, Morabito, F, Gentile, C, Capalbo, S, Gianni, A, Magni, M, Mettivier, V, Nunziata, G, Rizzoli, V, Giuliani, N, Crugnola, M, Bernasconi, C, Fregoni, V, Visani, G, Olivieri, A, Pizzuti, M, La Verde, G, Moscetti, A, Avvisati, G, Tirindelli, M, Longinotti, M, Podda, L, Gallo, E, Pregno, P, Dammacco, F, Perosa, F, Russo, D, Roccaro, A, Bacigalupo, A, Dominietto, A, Musolino, C, Quartarone, E, Tosi P, Motta MR, Rizzi S, Fanin R, Buttignol S, Foà R, Levi A, Calabrese E, Rambaldi A, Galli M, Rossi G, Ferrari S, Bringhen S, Leoni P, Offidani M, Polloni C, Corradini P, Montefusco V, Torelli G, Narni F, Fioritoni G, Spadano A, Cortelazzo S, Pescosta N, Billio A, Lambertenghi Deliliers G, Baldini L, Onida F, Annaloro C, La Nasa G, Ledda A, Zaccaria A, Cellini C, De Fabritiis P, Caravita T, Siniscalchi A, Cascavilla N, Bosi A, Semenzato G, Gugliotta L, Merli F, Gherlinzoni F, Angelucci E, Martelli M, Petti MC, Pisani F, Leone G, Rossi E, Za T, Fianchi L, Catania G, Spriano M, Ciceri F, Peccatori J, Girlanda S, Santoro A, Castagna L, Palmieri S, Nobile F, D'Arco AM, Levis A, Primon V, Tamiazzo S, Guardigni L, Pasini S, Gallamini A, Pietrantuono G, Martorelli MC, Fattori P, Pasquini E, Galieni P, Ruggieri M, Morandi S, Tajana M, Amadori D, Ronconi S, Cangini D, Ceccolini M, Gobbi M, Ballerini F, Pane F, Catalano L, Cangialosi C, Vallisa D, Lazzaro A, Paladini G, De Sabbata G, Mozzana R, Ciambelli F, Pinotti G, Rodeghiero F, Elice F, Cantore N, Volpe S, Pavone V, Mele A, POGLIANI, ENRICO MARIA, Rossini F, Liberati A, Majolino I, De Rosa L, Amadori S, Rizzo M, Lauria F, Gozzetti A, Aglietta M, Capaldi A, Quarta G, Mele G, Storti S, Fraticelli V, Morabito F, Gentile C, Capalbo S, Gianni A, Magni M, Mettivier V, Nunziata G, Rizzoli V, Giuliani N, Crugnola M, Bernasconi C, Fregoni V, Visani G, Olivieri A, Pizzuti M, La Verde G, Moscetti A, Avvisati G, Tirindelli M, Longinotti M, Podda L, Gallo E, Pregno P, Dammacco F, Perosa F, Russo D, Roccaro A, Bacigalupo A, Dominietto A, Musolino C, Quartarone E., Cavo, M, Pantani, L, Petrucci, M, Patriarca, F, Zamagni, E, Donnarumma, D, Crippa, C, Boccadoro, M, Perrone, G, Falcone, A, Nozzoli, C, Zambello, R, Masini, L, Furlan, A, Brioli, A, Derudas, D, Ballanti, S, Dessanti, M, De Stefano, V, Carella, A, Marcatti, M, Nozza, A, Ferrara, F, Callea, V, Califano, C, Pezzi, A, Baraldi, A, Grasso, M, Musto, P, Palumbo, A, Tosi, P, Motta, M, Rizzi, S, Fanin, R, Buttignol, S, Foà, R, Levi, A, Calabrese, E, Rambaldi, A, Galli, M, Rossi, G, Ferrari, S, Bringhen, S, Leoni, P, Offidani, M, Polloni, C, Corradini, P, Montefusco, V, Torelli, G, Narni, F, Fioritoni, G, Spadano, A, Cortelazzo, S, Pescosta, N, Billio, A, Lambertenghi Deliliers, G, Baldini, L, Onida, F, Annaloro, C, La Nasa, G, Ledda, A, Zaccaria, A, Cellini, C, De Fabritiis, P, Caravita, T, Siniscalchi, A, Cascavilla, N, Bosi, A, Semenzato, G, Gugliotta, L, Merli, F, Gherlinzoni, F, Angelucci, E, Martelli, M, Petti, M, Pisani, F, Leone, G, Rossi, E, Za, T, Fianchi, L, Catania, G, Spriano, M, Ciceri, F, Peccatori, J, Girlanda, S, Santoro, A, Castagna, L, Palmieri, S, Nobile, F, D'Arco, A, Levis, A, Primon, V, Tamiazzo, S, Guardigni, L, Pasini, S, Gallamini, A, Pietrantuono, G, Martorelli, M, Fattori, P, Pasquini, E, Galieni, P, Ruggieri, M, Morandi, S, Tajana, M, Amadori, D, Ronconi, S, Cangini, D, Ceccolini, M, Gobbi, M, Ballerini, F, Pane, F, Catalano, L, Cangialosi, C, Vallisa, D, Lazzaro, A, Paladini, G, De Sabbata, G, Mozzana, R, Ciambelli, F, Pinotti, G, Rodeghiero, F, Elice, F, Cantore, N, Volpe, S, Pavone, V, Mele, A, Pogliani, E, Rossini, F, Liberati, A, Majolino, I, De Rosa, L, Amadori, S, Rizzo, M, Lauria, F, Gozzetti, A, Aglietta, M, Capaldi, A, Quarta, G, Mele, G, Storti, S, Fraticelli, V, Morabito, F, Gentile, C, Capalbo, S, Gianni, A, Magni, M, Mettivier, V, Nunziata, G, Rizzoli, V, Giuliani, N, Crugnola, M, Bernasconi, C, Fregoni, V, Visani, G, Olivieri, A, Pizzuti, M, La Verde, G, Moscetti, A, Avvisati, G, Tirindelli, M, Longinotti, M, Podda, L, Gallo, E, Pregno, P, Dammacco, F, Perosa, F, Russo, D, Roccaro, A, Bacigalupo, A, Dominietto, A, Musolino, C, Quartarone, E, Tosi P, Motta MR, Rizzi S, Fanin R, Buttignol S, Foà R, Levi A, Calabrese E, Rambaldi A, Galli M, Rossi G, Ferrari S, Bringhen S, Leoni P, Offidani M, Polloni C, Corradini P, Montefusco V, Torelli G, Narni F, Fioritoni G, Spadano A, Cortelazzo S, Pescosta N, Billio A, Lambertenghi Deliliers G, Baldini L, Onida F, Annaloro C, La Nasa G, Ledda A, Zaccaria A, Cellini C, De Fabritiis P, Caravita T, Siniscalchi A, Cascavilla N, Bosi A, Semenzato G, Gugliotta L, Merli F, Gherlinzoni F, Angelucci E, Martelli M, Petti MC, Pisani F, Leone G, Rossi E, Za T, Fianchi L, Catania G, Spriano M, Ciceri F, Peccatori J, Girlanda S, Santoro A, Castagna L, Palmieri S, Nobile F, D'Arco AM, Levis A, Primon V, Tamiazzo S, Guardigni L, Pasini S, Gallamini A, Pietrantuono G, Martorelli MC, Fattori P, Pasquini E, Galieni P, Ruggieri M, Morandi S, Tajana M, Amadori D, Ronconi S, Cangini D, Ceccolini M, Gobbi M, Ballerini F, Pane F, Catalano L, Cangialosi C, Vallisa D, Lazzaro A, Paladini G, De Sabbata G, Mozzana R, Ciambelli F, Pinotti G, Rodeghiero F, Elice F, Cantore N, Volpe S, Pavone V, Mele A, POGLIANI, ENRICO MARIA, Rossini F, Liberati A, Majolino I, De Rosa L, Amadori S, Rizzo M, Lauria F, Gozzetti A, Aglietta M, Capaldi A, Quarta G, Mele G, Storti S, Fraticelli V, Morabito F, Gentile C, Capalbo S, Gianni A, Magni M, Mettivier V, Nunziata G, Rizzoli V, Giuliani N, Crugnola M, Bernasconi C, Fregoni V, Visani G, Olivieri A, Pizzuti M, La Verde G, Moscetti A, Avvisati G, Tirindelli M, Longinotti M, Podda L, Gallo E, Pregno P, Dammacco F, Perosa F, Russo D, Roccaro A, Bacigalupo A, Dominietto A, Musolino C, and Quartarone E.

Abstract

In a randomized, phase 3 study, superior complete/near-complete response (CR/nCR) rates and extended progression-free survival were demonstrated with bortezomib-thalidomide-dexamethasone (VTD) versus thalidomide-dexamethasone (TD) as induction therapy before, and consolidation after, double autologous stem cell transplantation for newly diagnosed myeloma patients (intention-to-treat analysis; VTD, n = 236; TD, n = 238). This per-protocol analysis (VTD, n = 160; TD, n = 161) specifically assessed the efficacy and safety of consolidation with VTD or TD. Before starting consolidation, CR/nCR rates were not significantly different in the VTD (63.1%) and TD arms (54.7%). After consolidation, CR (60.6% vs 46.6%) and CR/nCR (73.1% vs 60.9%) rates were significantly higher for VTD-treated versus TD-treated patients. VTD consolidation significantly increased CR and CR/nCR rates, but TD did not (McNemar test). With a median follow-up of 30.4 months from start of consolidation, 3-year progression-free survival was significantly longer for the VTD group (60% vs 48% for TD). Grade 2 or 3 peripheral neuropathy (8.1% vs 2.4%) was more frequent with VTD (grade 3, 0.6%) versus TD consolidation. The superior efficacy of VTD versus TD as induction was retained despite readministration as consolidation therapy after double autologous transplantation. VTD consolidation therapy significantly contributed to improved clinical outcomes observed for patients randomly assigned to the VTD arm of the study. The study is registered at www.clinicaltrials.gov as #NCT01134484.

Published
2012

42. Mismatched hematopoietic stem cell transplants in elderly patients

Author

Tabilio, Antonio, Velardi, Andrea, Terenzi, A., Ballanti, S., Felicini, R., Carotti, A., Falcinelli, F., Falzetti, Franca, Minelli, O., and Martelli, Massimo Fabrizio

Subjects
paziente anziano, trapianto incompatibile, cellule staminali
Published
2000

45. Efficacy and tolerability of bendamustine, bortezomib and dexamethasone in patients with relapsed-refractory multiple myeloma: a phase II study

Author

Offidani, M, primary, Corvatta, L, additional, Maracci, L, additional, Liberati, A M, additional, Ballanti, S, additional, Attolico, I, additional, Caraffa, P, additional, Alesiani, F, additional, Caravita di Toritto, T, additional, Gentili, S, additional, Tosi, P, additional, Brunori, M, additional, Derudas, D, additional, Ledda, A, additional, Gozzetti, A, additional, Cellini, C, additional, Malerba, L, additional, Mele, A, additional, Andriani, A, additional, Galimberti, S, additional, Mondello, P, additional, Pulini, S, additional, Coppetelli, U, additional, Fraticelli, P, additional, Olivieri, A, additional, and Leoni, P, additional

Published
2013
Full Text
View/download PDF

47. A451 Superiority of VTD over TD Incorporated Into ASCT for Newly Diagnosed MM

Author

Cavo, M, primary, Zambello, R, additional, Nozzoli, C, additional, Gugliotta, L, additional, Pantani, L, additional, Patriarca, F, additional, Petrucci, MT, additional, Tacchetti, P, additional, Galli, M, additional, Ceccolini, M, additional, Di Raimondo, F, additional, Rossi, G, additional, Zamagni, E, additional, Bringhen, S, additional, Narni, F, additional, Tosi, P, additional, Montefusco, V, additional, Offidani, M, additional, Brioli, A, additional, Pallotti, MC, additional, Spadano, T, additional, Pescosta, N, additional, Goldaniga, M, additional, Ledda, A, additional, Perrone, G, additional, Petrucci, A, additional, Caravita, T, additional, Cascavilla, N, additional, Gherlinzoni, F, additional, De Stefano, V, additional, Angelucci, E, additional, Petti, MC, additional, Ballanti, S, additional, Callea, V, additional, and Baccarani, M, additional

Published
2009
Full Text
View/download PDF

49. Fatal herpesvirus-6 encephalitis in a recipient of a T-cell-depleted peripheral blood stem cell transplant from a 3-loci mismatched related donor

Author

Tiacci, E., Mario LUPPI, Barozzi, P., Gurdo, G., Tabilio, A., Ballanti, S., Torelli, G., and Aversa, F.

Subjects
Male, Transplantation Conditioning, Herpesvirus 6, Human, Hematopoietic Stem Cell Transplantation, Graft vs Host Disease, Herpesviridae Infections, Middle Aged, Polymerase Chain Reaction, Lymphocyte Depletion, Tissue Donors, T-cell-depleted mismatched transplant, Fatal Outcome, HHV-6 encephalitis, Histocompatibility, Cytomegalovirus Infections, DNA, Viral, Humans, Virus Activation, Encephalitis, Viral, Ganciclovir, Immunosuppressive Agents, Foscarnet
Abstract

Human herpesvirus-6 (HHV-6), like all the other herpes viruses, remains latent in host cells after primary infection but can be reactivated in immunocompromised patients causing fever, skin rash, bone marrow (BM) suppression, pneumonitis, sinusitis and meningoencephalitis. We describe the case of a man with chronic myelogenous leukemia who developed encephalitis associated with acute graft-versus-host disease two months after a T-cell-depleted mismatched peripheral blood stem cell transplant. Magnetic resonance images of the brain revealed multiple bilateral foci of signal abnormality. HHV-6 was the only pathogen detected in cerebrospinal fluid by PCR. Treatment with both ganciclovir and foscarnet was unsuccessful and the patient gradually deteriorated and died. Other cases of HHV-6 encephalitis after bone marrow transplantation are reviewed.

50. SEIFEM 2016 STUDY: INCIDENCE OF PROBABLE AND PROVEN INVASIVE ASPERGILLOSIS IN PATIENTS WITH ACUTE MYELOID LEUKEMIA DURING CONSOLIDATION THERAPY

Author

Del Principe, M. I., Di Blasi, R., Verga, L., anna candoni, Potenza, L., Ballanti, S., Cattaneo, C., Delia, M., Decembrino, N., Melillo, L., Castagnola, C., Nadali, G., Fanci, R., Ferrari, A., Fracchiolla, N. S., Iovino, L., Lessi, F., Veggia, B., Offidani, M., Picardi, M., Prezioso, L., Rambaldi, B., Marchesi, F., Annibali, O., Zama, D., Mancini, V., Salutari, P., Garzia, M. G., Vacca, A., Cesaro, S., Paolis, M. R., Invernizzi, R., Perruccio, K., Mitra, M. E., Quinto, A. M., Venditti, A., Busca, A., Aversa, F., and Pagano, L.

Subjects
acute myeloid leukemia, aspergillosis, chemotherapy, aspergillosis, acute myeloid leukemia, chemotherapy

Catalog

Books, media, physical & digital resources
See catalog results